Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial, SAKK 19/05.
Francesco Zappa(Friedrich Schiller University Jena), Miklos Pless(Ontario Institute for Cancer Research), C. Droege(University Hospital of Basel), Karin Ribi, Daniel Rauch(Washington University in St. Louis), Florent Baty(University of St.Gallen), Roger von Moos(Kantonsspital Graubünden), Adrian F. Ochsenbein(University of Bern), S. Crowe, Martin Brutsche(University of Basel), Elisabeth Oppliger Leibundgut(University Hospital of Bern), Michael Mayer(Swiss Group For Clinical Cancer Research), Peter Schmid(St Bartholomew's Hospital), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Peter Brauchli(University of St.Gallen), Patrizia Froesch(Institute of Oncology Research), Lukas Bubendorf(University of Basel), R. Stahel, Daniel Betticher
Cited by 3
Related Papers
Tissue microarrays for high-throughput molecular profiling of tumor specimens
|Nature Medicine|1998|4.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k